Red Light Therapy for Cancer Treatment: A Comprehensive Guide to Photobiomodulation
Share
Red light therapy, also known as photobiomodulation (PBM) or low-level light therapy (LLLT), has emerged as a promising complementary approach in cancer care. This non-invasive treatment uses specific wavelengths of red and near-infrared light to stimulate cellular function, reduce inflammation, and support healing processes. Whilst red light therapy is not a standalone cure for cancer, growing research suggests it may offer significant benefits for cancer patients, particularly in managing treatment side effects and potentially enhancing therapeutic outcomes.
What Is Red Light Therapy?
Red light therapy involves exposing the body to low levels of red or near-infrared light, typically in the wavelength range of 630-850 nanometres. Unlike ultraviolet (UV) light, which can damage skin and DNA, red and near-infrared wavelengths penetrate tissue safely, reaching depths of several centimetres beneath the skin surface.
The therapeutic mechanism operates at the cellular level, primarily through the stimulation of mitochondria—the energy-producing structures within cells. When mitochondria absorb red and near-infrared light, they produce more adenosine triphosphate (ATP), the cellular energy currency. This increased energy production enhances cellular function, promotes tissue repair, reduces oxidative stress, and modulates inflammatory responses.
Red light therapy devices include LED panels, handheld devices, light beds, and targeted laser systems. Treatment sessions typically last 10-20 minutes and can be administered several times per week, depending on the specific protocol and therapeutic goals.
The Science Behind Red Light Therapy and Cancer
Cellular Mechanisms of Photobiomodulation
Research published in Photomedicine and Laser Surgery has identified multiple mechanisms through which red light therapy influences cellular behaviour relevant to cancer treatment:
Mitochondrial Stimulation: Red light photons are absorbed by cytochrome c oxidase, a key enzyme in the mitochondrial respiratory chain. This absorption increases ATP production, enhancing cellular energy availability and function. For cancer patients experiencing fatigue and cellular dysfunction from chemotherapy or radiation, this energy boost can support recovery and quality of life.
Reduction of Oxidative Stress: Cancer treatments often generate excessive reactive oxygen species (ROS), leading to oxidative damage in healthy tissues. Studies in Lasers in Medical Science demonstrate that red light therapy can reduce oxidative stress by enhancing antioxidant enzyme activity, including superoxide dismutase and catalase, protecting healthy cells from treatment-related damage.
Anti-Inflammatory Effects: Chronic inflammation contributes to cancer progression and treatment complications. Red light therapy has been shown to reduce pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, whilst increasing anti-inflammatory mediators. This modulation of the inflammatory response may help manage treatment side effects and create a less favourable environment for cancer progression.
Improved Circulation and Oxygenation: Photobiomodulation promotes vasodilation and angiogenesis in healthy tissues, improving blood flow and oxygen delivery. Enhanced circulation supports nutrient delivery, waste removal, and immune cell trafficking—all critical for healing and recovery during cancer treatment.
The Dual Nature of Light Therapy in Cancer
An important consideration in cancer care is the potential dual effect of red light therapy. Whilst PBM can support healthy tissue function and reduce side effects, questions remain about whether it might also stimulate cancer cell growth. Research in this area presents a nuanced picture:
Studies published in Anticancer Research suggest that the effects of red light therapy may differ between normal cells and cancer cells. Some research indicates that whilst healthy cells benefit from increased ATP production and enhanced function, cancer cells—which already have dysfunctional mitochondria and altered metabolism—may not respond in the same way. In fact, some studies suggest that specific wavelengths and dosing parameters may selectively harm cancer cells whilst protecting normal tissue.
However, this remains an area of active investigation, and cancer patients should only use red light therapy under professional medical supervision, particularly during active treatment phases.
Clinical Applications of Red Light Therapy in Cancer Care
Managing Oral Mucositis
One of the most well-established applications of red light therapy in oncology is the prevention and treatment of oral mucositis—painful inflammation and ulceration of the mouth and throat lining caused by chemotherapy and radiation therapy. This debilitating side effect affects up to 80% of patients receiving high-dose chemotherapy or head and neck radiation.
The Multinational Association of Supportive Care in Cancer (MASCC) and the International Society of Oral Oncology (ISOO) have issued clinical practice guidelines recommending photobiomodulation for preventing oral mucositis in patients undergoing haematopoietic stem cell transplantation and head and neck radiation therapy.
Research published in Supportive Care in Cancer demonstrates that prophylactic red light therapy can reduce the incidence and severity of oral mucositis by up to 50%. Treatment protocols typically involve applying red light (wavelengths of 630-660nm) to the oral cavity for several minutes daily throughout the chemotherapy or radiation course.
The mechanism involves enhanced cellular repair, reduced inflammation, improved blood flow to affected tissues, and accelerated healing of damaged mucous membranes. Patients experience less pain, improved ability to eat and drink, reduced need for opioid pain medications, and better overall quality of life during treatment.
Reducing Radiation Dermatitis
Radiation dermatitis—skin inflammation and damage resulting from radiation therapy—affects the majority of cancer patients receiving radiotherapy. Symptoms range from mild redness and dryness to severe blistering, ulceration, and pain.
Clinical trials published in Lasers in Surgery and Medicine have investigated red light therapy for preventing and treating radiation dermatitis. Results indicate that photobiomodulation can reduce the severity of skin reactions, accelerate healing, decrease pain, and improve patient comfort.
Treatment involves applying red or near-infrared light to the irradiated skin area before, during, and after radiation therapy sessions. The light therapy stimulates collagen production, enhances tissue repair, reduces inflammatory responses, and improves skin barrier function.
Managing Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy (CIPN) causes numbness, tingling, pain, and loss of function in the hands and feet, affecting up to 70% of patients receiving neurotoxic chemotherapy agents such as platinum compounds, taxanes, and vinca alkaloids. CIPN can be debilitating and may persist long after treatment completion.
Research in Photomedicine and Laser Surgery suggests that red light therapy may help manage CIPN symptoms by promoting nerve regeneration, reducing inflammation in nerve tissues, improving microcirculation to peripheral nerves, and modulating pain signalling pathways.
Whilst large-scale clinical trials are still needed, preliminary studies and case reports indicate that regular red light therapy sessions applied to affected extremities may reduce pain intensity, improve sensory function, and enhance quality of life for patients suffering from CIPN.
Supporting Lymphoedema Management
Lymphoedema—chronic swelling caused by lymphatic system damage from cancer surgery or radiation—affects millions of cancer survivors, particularly those treated for breast cancer. This condition can cause discomfort, limited mobility, increased infection risk, and psychological distress.
Studies published in Lasers in Medical Science have explored red light therapy as an adjunct treatment for lymphoedema. Photobiomodulation may support lymphatic function by stimulating lymphatic vessel formation, reducing fibrosis in affected tissues, decreasing inflammation, and improving tissue metabolism.
When combined with standard lymphoedema management techniques such as compression therapy and manual lymphatic drainage, red light therapy may enhance treatment outcomes and symptom relief.
Reducing Cancer-Related Fatigue
Cancer-related fatigue is one of the most common and distressing symptoms experienced by cancer patients, affecting up to 90% of individuals during treatment and persisting in many survivors. This profound exhaustion is not relieved by rest and significantly impacts quality of life.
The mitochondrial-stimulating effects of red light therapy offer potential benefits for managing cancer-related fatigue. By enhancing cellular energy production, improving sleep quality, reducing inflammation, and supporting overall cellular function, photobiomodulation may help alleviate fatigue symptoms.
Research published in Photobiomodulation, Photomedicine, and Laser Surgeryhas investigated whole-body red light therapy for cancer-related fatigue, with preliminary results suggesting improvements in energy levels, physical function, and overall wellbeing. However, more extensive clinical trials are needed to establish optimal protocols and confirm efficacy.
Red Light Therapy Protocols for Cancer Patients
Treatment Parameters
Effective red light therapy requires specific parameters tailored to the therapeutic goal:
Wavelength: Red light (630-680nm) penetrates 5-10mm into tissue and is effective for superficial conditions like oral mucositis and skin issues. Near-infrared light (800-850nm) penetrates deeper (up to 50mm) and is beneficial for deeper tissues, nerves, and systemic effects.
Power Density: Therapeutic devices typically deliver 10-100 mW/cm², with higher power densities allowing shorter treatment times.
Energy Dose: Measured in joules per square centimetre (J/cm²), optimal doses range from 2-10 J/cm² depending on the condition being treated. The biphasic dose response means that too little or too much light may be ineffective—precise dosing is crucial.
Treatment Duration: Sessions typically last 10-20 minutes, depending on device power and target dose.
Frequency: Most protocols involve daily or several-times-weekly treatments, with consistency being key to achieving therapeutic benefits.
Safety Considerations
Red light therapy is generally considered safe with minimal side effects when used appropriately. However, cancer patients should observe important precautions:
Medical Supervision: Always consult with your oncology team before beginning red light therapy, particularly during active cancer treatment.
Avoid Direct Tumour Irradiation: Until more research clarifies the effects of red light on active tumours, it’s prudent to avoid applying light directly to known cancer sites.
Eye Protection: Near-infrared wavelengths can potentially affect the eyes; appropriate eye protection should be used during facial or whole-body treatments.
Device Quality: Use medical-grade devices with validated wavelengths and power outputs. Consumer devices vary widely in quality and may not deliver therapeutic parameters.
Timing with Treatments: Discuss optimal timing of red light therapy sessions in relation to chemotherapy and radiation treatments with your healthcare team.
The Future of Red Light Therapy in Oncology
Research into photobiomodulation for cancer care continues to expand, with ongoing clinical trials investigating new applications and refining treatment protocols. Areas of particular interest include:
Combination Therapies:Exploring how red light therapy might enhance the effectiveness of conventional cancer treatments whilst reducing side effects.
Personalised Protocols: Developing individualised treatment parameters based on cancer type, treatment regimen, and patient characteristics.
Mechanistic Understanding: Deepening knowledge of how different wavelengths, doses, and timing affect both cancer cells and healthy tissues.
Long-Term Outcomes: Investigating whether red light therapy during active treatment influences long-term survival and recurrence rates.
Home-Based Therapy: Evaluating the feasibility and effectiveness of patient-administered red light therapy for managing chronic treatment side effects.
Conclusion
Red light therapy represents a promising complementary approach in comprehensive cancer care. With strong evidence supporting its use for managing oral mucositis and emerging research suggesting benefits for radiation dermatitis, peripheral neuropathy, lymphoedema, and cancer-related fatigue, photobiomodulation offers cancer patients a non-invasive, low-risk option for improving quality of life during and after treatment.
However, red light therapy should never replace conventional cancer treatments. Instead, it works best as part of an integrative approach, combining evidence-based complementary therapies with standard oncology care. As research continues to evolve, the role of photobiomodulation in cancer treatment will become clearer, potentially offering new strategies for supporting patients throughout their cancer journey.
If you’re considering red light therapy as part of your cancer care plan, work closely with healthcare professionals experienced in integrative oncology to develop a safe, personalised protocol that complements your conventional treatment and supports your overall healing and wellbeing.
Scientific References
1. Antunes HS, Herchenhorn D, Small IA, et al. Long-term survival of a randomized phase III trial of head and neck cancer patients receiving concurrent chemoradiation therapy with or without low-level laser therapy (LLLT) to prevent oral mucositis. Oral Oncology. 2017;71:11-15.
2. Barolet D, Christiaens F, Hamblin MR. Infrared and skin: Friend or foe. Journal of Photochemistry and Photobiology B: Biology. 2016;155:78-85.
3. Bensadoun RJ, Epstein JB, Nair RG, et al. Safety and efficacy of photobiomodulation therapy in oncology: A systematic review. Cancer Medicine. 2020;9(22):8279-8300.
4. Chow RT, Johnson MI, Lopes-Martins RA, Bjordal JM. Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis of randomised placebo or active-treatment controlled trials. The Lancet. 2009;374(9705):1897-1908.
5. de Freitas LF, Hamblin MR. Proposed mechanisms of photobiomodulation or low-level light therapy. IEEE Journal of Selected Topics in Quantum Electronics. 2016;22(3):7000417.
6. Dungel P, Hartinger J, Chaudary S, et al. Low level light therapy by LED of different wavelength induces angiogenesis and improves ischemic wound healing. Lasers in Surgery and Medicine. 2014;46(10):773-780.
7. Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophysics. 2017;4(3):337-361.
8. Huang YY, Sharma SK, Carroll J, Hamblin MR. Biphasic dose response in low level light therapy - an update. Dose-Response. 2011;9(4):602-618.
9. Karu TI, Pyatibrat LV, Afanasyeva NI. Cellular effects of low power laser therapy can be mediated by nitric oxide. Lasers in Surgery and Medicine. 2005;36(4):307-314.
10. Leal-Junior EC, Johnson DS, Saltmarche A, Demchak T. Adjunctive use of combination of super-pulsed laser and light-emitting diodes phototherapy on nonspecific knee pain: double-blinded randomized placebo-controlled trial. Lasers in Medical Science. 2014;29(6):1839-1847.
11. Migliorati C, Hewson I, Lalla RV, et al. Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Supportive Care in Cancer. 2013;21(1):333-341.
12. Robijns J, Censabella S, Bulens P, et al. The use of low-level light therapy in supportive care for patients with breast cancer: review of the literature. Lasers in Medical Science. 2017;32(1):229-242.
13. Salehpour F, Mahmoudi J, Kamari F, et al. Brain photobiomodulation therapy: a narrative review. Molecular Neurobiology. 2018;55(8):6601-6636.
14. Zecha JA, Raber-Durlacher JE, Nair RG, et al. Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations. Supportive Care in Cancer. 2016;24(6):2781-2792.
15. Zecha JA, Raber-Durlacher JE, Nair RG, et al. Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 2: proposed applications and treatment protocols. Supportive Care in Cancer. 2016;24(6):2793-2805.